Aside from making coronavirus vaccines, Moderna (NASDAQ: MRNA) , Pfizer (NYSE: PFE) , and Novavax (NASDAQ: NVAX) have one big thing in common; whatever happens in June will be critical for their share prices. But June isn't when the trio will be reporting earnings or when they're scheduled to be dropping big announcements; rather, it's when regulators at the U.S. Food and Drug Administration (FDA) are slated to weigh in on their jabs.
If these companies get a green light, it'll mean more revenue in the near future. If regulators rebuff them, it'll be devastating for their shareholders. Let's look at exactly what's on the docket next month so that you'll know whether it might make sense to prepare to make a fresh purchase -- or perhaps a near-term sale to avoid the considerable risk exposure.
Image source: Getty Images.
For further details see:
Here's Why June Could Make Or Break These 3 Vaccine Stocks